Oncolytic measles virus retargeting by ligand display

Pavlos Msaouel, Ianko D. Iankov, Cory Allen, Stephen J. Russell, Evanthia Galanis

Research output: Chapter in Book/Report/Conference proceedingChapter

14 Scopus citations

Abstract

Despite significant advances in recent years, treatment of metastatic malignancies remains a significant challenge. There is an urgent need for development of novel therapeutic approaches. Virotherapy approaches have considerable potential, and among them measles virus (MV) vaccine strains have emerged as a promising oncolytic platform. Retargeted MV strains deriving from the Edmonston vaccine lineage (MV-Edm) have shown comparable antitumor efficacy to unmodified strains against receptor expressing tumor cells with improved therapeutic index. Here, we describe the construction, rescue, amplification, and titration of fully retargeted MV-Edm derivatives displaying tumor specific receptor binding ligands on the viral surface in combination with H protein CD46 and SLAM entry ablating mutations.

Original languageEnglish (US)
Title of host publicationOncolytic Viruses
Subtitle of host publicationMethods and Protocols
PublisherHumana Press Inc.
Pages141-162
Number of pages22
ISBN (Print)9781617793394
DOIs
StatePublished - 2012

Publication series

NameMethods in Molecular Biology
Volume797
ISSN (Print)1064-3745
ISSN (Electronic)1940-6029

Keywords

  • Measles engineering
  • Measles retargeting
  • Oncolytic measles virus
  • Virotherapy

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics

Fingerprint Dive into the research topics of 'Oncolytic measles virus retargeting by ligand display'. Together they form a unique fingerprint.

  • Cite this

    Msaouel, P., Iankov, I. D., Allen, C., Russell, S. J., & Galanis, E. (2012). Oncolytic measles virus retargeting by ligand display. In Oncolytic Viruses: Methods and Protocols (pp. 141-162). (Methods in Molecular Biology; Vol. 797). Humana Press Inc.. https://doi.org/10.1007/978-1-61779-340-0_11